Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6-Reference-Cited by-同舟云学术

Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6

Published:2022-02-01 Issue:1 Volume:35 Page:60-70
ISSN:0882-8245
Container-title:Viral Immunology
language:en
Short-container-title:Viral Immunology

Author:

Ponthieux Fanny¹^ORCID,Dauby Nicolas²³,Maillart Evelyne⁴,Fils Jean-François⁵,Smet Julie¹,Claus Marc⁶,Besse-Hammer Tatiana⁷,Bels David De⁸,Corazza Francis¹⁹,Nagant Carole¹

Affiliation:

1. Immunology Department, LHUB-ULB, Université libre de Bruxelles (ULB), Brussels, Belgium.

2. Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université libre de Bruxelles (ULB), Brussels, Belgium.

3. Institute for Medical Immunology, Université libre de Bruxelles (ULB), Brussels, Belgium.

4. Department of Infectious Disease, Brugmann University Hospital, Brussels, Belgium.

5. Ars Statistica, Brussels, Belgium.

6. Department of Intensive Care, Centre Hospitalier Universitaire Saint-Pierre, Université libre de Bruxelles (ULB), Brussels, Belgium.

7. Clinical Research Department, Brugmann University Hospital, Brussels, Belgium.

8. Department of Intensive Care, Brugmann University Hospital, Brussels, Belgium.

9. Laboratory of Translational Research, Brugmann University Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Molecular Medicine,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/vim.2021.0111

Reference32 articles.

1. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context

2. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19

3. IL-6 biology: implications for clinical targeting in rheumatic disease

4. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants

5. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19;Frontiers in Immunology;2023-07-06

2. Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the “fail-and-learn” strategy during the first two waves of the pandemic in 2020;Patient Safety in Surgery;2023-04-11

3. Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the “fail-and-learn” strategy during the first two waves of the pandemic in 2020;2023-02-20

4. Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome;PLOS ONE;2023-02-15

5. Coagulopathy in COVID-19 and anticoagulation clinical trials;Best Practice & Research Clinical Haematology;2022-09